Population pharmacokinetics of carboplatin in children

Clinical Pharmacology and Therapeutics
E ChatelutP Canal

Abstract

In pediatric patients, administration of carboplatin according to body surface area results in a large variation in the area under the plasma ultrafilterable carboplatin concentration versus time curve. A population pharmacokinetic study using the NONMEM program was undertaken to determine the effects of a variety of covariates on the clearance of ultrafilterable carboplatin. Plasma carboplatin pharmacokinetics were determined in 57 children (2 months to 18 years old, with serum creatinine levels ranging from 27 to 268 mumol/L) treated for various tumor types. The best fit corresponded to the formula: clearance (ml/min) = 2.85.weight.(1-0.00357.serum creatinine).(1-0.372.Np) + 8.7 (with serum creatinine in micromoles per liter, weight in kilograms, and Np = 1 or 0 for unilateral nephrectomy or not, respectively). The interindividual variability in clearance, as expressed by the coefficient of variation, decreased from 74% (no covariates) to 49% by taking account of weight, and to 29% under the final regression formula. The ability of this formula to predict carboplatin clearance in children should be evaluated prospectively and compared to a method based on the determination of the glomerular filtration rate.

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I JodrellE Wiltshaw
Jun 1, 1992·Clinical Pharmacology and Therapeutics·T MaddenJ H Rodman
Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HorwichW F Hendry
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·B T SørensenA Jakobsen
Jan 1, 1990·Medical and Pediatric Oncology·F DozJ M Zucker
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C P BelaniD A Van Echo
Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Apr 19, 1995·Journal of the National Cancer Institute·E ChatelutR Bugat
Jun 1, 1994·Archives of Disease in Childhood·L D Voss, B J Bailey
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·R RiccardiR Mastrangelo
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F Doz, R Pinkerton
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R NewellM C Stevens
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N M MarinaW Meyer
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L M ReynoR Sridhara
Oct 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B PengD R Newell

❮ Previous
Next ❯

Citations

Feb 5, 1997·Journal of the National Cancer Institute·Y FujiwaraM J Egorin
Dec 16, 2005·The AAPS Journal·Bernd MeibohmJeffrey S Barrett
Aug 26, 2004·The Annals of Pharmacotherapy·Ene I Ette, Paul J Williams
Dec 8, 2004·Critical Reviews in Oncology/hematology·E GroningerS S N de Graaf
Jul 10, 2008·Clinical Pharmacokinetics·Anthe S ZandvlietAlwin D R Huitema
Dec 4, 2008·Fundamental & Clinical Pharmacology·Etienne Chatelut
Oct 14, 2009·British Journal of Haematology·Georg HempelJoachim Boos
Jan 30, 2010·Therapeutic Drug Monitoring·Andreas LindauerUlrich Jaehde
Dec 12, 2012·British Journal of Clinical Pharmacology·Johan G C van HasseltAlwin D R Huitema
Jul 11, 2003·Anti-cancer Drugs·Georg HempelJoachim Boos
Sep 13, 2003·British Journal of Clinical Pharmacology·Georg HempelJoachim Boos
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M GalloS D Baker
Apr 6, 1999·British Journal of Clinical Pharmacology·L Lennard
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H ThomasD R Newell
Jun 5, 2003·Anti-cancer Drugs·S UrienF Lokiec
Nov 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Corine EkhartJos H Beijnen
Mar 13, 2021·Frontiers in Pediatrics·Alan AbdullaMatthijs de Hoog
Apr 15, 2011·Cancer Treatment Reviews·Hendrik van den BergJos H Beijnen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.